These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 17196297)

  • 1. Pharmaceutical impurities: analytical, toxicological and regulatory perspectives.
    Basak AK; Raw AS; Yu LX
    Adv Drug Deliv Rev; 2007 Jan; 59(1):1-2. PubMed ID: 17196297
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmaceutical impurities: regulatory perspective for Abbreviated New Drug Applications.
    Basak AK; Raw AS; Al Hakim AH; Furness S; Samaan NI; Gill DS; Patel HB; Powers RF; Yu L
    Adv Drug Deliv Rev; 2007 Jan; 59(1):64-72. PubMed ID: 17196703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overall impact of the regulatory requirements for genotoxic impurities on the drug development process.
    Giordani A; Kobel W; Gally HU
    Eur J Pharm Sci; 2011 May; 43(1-2):1-15. PubMed ID: 21420491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assuring quality of drugs by monitoring impurities.
    Ahuja SS
    Adv Drug Deliv Rev; 2007 Jan; 59(1):3-11. PubMed ID: 17218038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toxicological overview of impurities in pharmaceutical products.
    Jacobson-Kram D; McGovern T
    Adv Drug Deliv Rev; 2007 Jan; 59(1):38-42. PubMed ID: 17188779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impurities in drug substances and drug products: new approaches to quantification and qualification.
    Berridge JC
    J Pharm Biomed Anal; 1995 Dec; 14(1-2):7-12. PubMed ID: 8833961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug impurities: problems and regulations.
    Pifferi G; Mannucci A
    Boll Chim Farm; 1999 Nov; 138(10):500-7. PubMed ID: 10765465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of degradant profiling in active pharmaceutical ingredients and drug products.
    Alsante KM; Ando A; Brown R; Ensing J; Hatajik TD; Kong W; Tsuda Y
    Adv Drug Deliv Rev; 2007 Jan; 59(1):29-37. PubMed ID: 17187892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elemental impurities in pharmaceutical products adding fuel to the fire.
    Maithani M; Raturi R; Sharma P; Gupta V; Bansal P
    Regul Toxicol Pharmacol; 2019 Nov; 108():104435. PubMed ID: 31376414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impurities in generic pharmaceutical development.
    Kovaleski J; Kraut B; Mattiuz A; Giangiulio M; Brobst G; Cagno W; Kulkarni P; Rauch T
    Adv Drug Deliv Rev; 2007 Jan; 59(1):56-63. PubMed ID: 17196702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategies for the investigation and control of process-related impurities in drug substances.
    Argentine MD; Owens PK; Olsen BA
    Adv Drug Deliv Rev; 2007 Jan; 59(1):12-28. PubMed ID: 17189658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zero risk and zero benefit: some thoughts on the control of genotoxic impurities.
    Grosso J
    Curr Opin Drug Discov Devel; 2009 Nov; 12(6):730-1. PubMed ID: 19894186
    [No Abstract]   [Full Text] [Related]  

  • 13. Identification, control strategies, and analytical approaches for the determination of potential genotoxic impurities in pharmaceuticals: a comprehensive review.
    Reddy AV; Jaafar J; Umar K; Majid ZA; Aris AB; Talib J; Madhavi G
    J Sep Sci; 2015 Mar; 38(5):764-79. PubMed ID: 25556762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progress in QSAR toxicity screening of pharmaceutical impurities and other FDA regulated products.
    Kruhlak NL; Contrera JF; Benz RD; Matthews EJ
    Adv Drug Deliv Rev; 2007 Jan; 59(1):43-55. PubMed ID: 17229485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adulteration of drugs and foods: compendial approaches to lowering risk.
    Abernethy DR; Sheehan C; Griffiths JC; Williams RL;
    Clin Pharmacol Ther; 2009 Apr; 85(4):444-7. PubMed ID: 18463621
    [No Abstract]   [Full Text] [Related]  

  • 16. Control and analysis of alkyl and benzyl halides and other related reactive organohalides as potential genotoxic impurities in active pharmaceutical ingredients (APIs).
    Elder DP; Lipczynski AM; Teasdale A
    J Pharm Biomed Anal; 2008 Nov; 48(3):497-507. PubMed ID: 18657926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Finding key impurities in different manufacturing routes of a drug substance using liquid chromatography/mass spectrometry followed by principal components analysis.
    Carrier D; Eckers C; Arnoult T; Thurston T; Major H
    Rapid Commun Mass Spectrom; 2007; 21(23):3946-8. PubMed ID: 17975854
    [No Abstract]   [Full Text] [Related]  

  • 18. [Study of the quality of laboratory chemicals and reagents, used in biochemical laboratories of the Institutes of National Health. V. Determination of water and other impurities in organic solvents].
    Sarsúnová M; Schmidt K; Remen J
    Cesk Farm; 1978 Oct; 27(8):335-8. PubMed ID: 743750
    [No Abstract]   [Full Text] [Related]  

  • 19. Analytical control of genotoxic impurities in the pazopanib hydrochloride manufacturing process.
    Liu DQ; Chen TK; McGuire MA; Kord AS
    J Pharm Biomed Anal; 2009 Sep; 50(2):144-50. PubMed ID: 19427156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impurities in organic synthetic drugs: a review of regulatory and toxicological considerations.
    Mahoney K; Scales MD; Tucker ML
    Adverse Drug React Toxicol Rev; 1993; 12(2):129-38. PubMed ID: 8357945
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.